Abstract:DNA has a strong affinity for many heterocyclic aromatic dyes, such as acridine and its derivatives. Lerman in 1961 first proposed intercalation as the source of this affinity, and this mode of DNA binding has since attracted considerable research scrutiny. Organic intercalators can inhibit nucleic acid synthesis in vivo, and they are now common anticancer drugs in clinical therapy. The covalent attachment of organic intercalators to transition metal coordination complexes, yielding metallointercalators, can lead to novel DNA interactions that influence biological activity. Metal complexes with σ-bonded aromatic side arms can act as dual-function complexes: they bind to DNA both by metal coordination and through intercalation of the attached aromatic ligand. These aromatic side arms introduce new modes of DNA binding, involving mutual interactions of functional groups held in close proximity. The biological activity of both cis- and trans-diamine Pt(II) complexes is dramatically enhanced by the addition of σ-bonded intercalators. We have explored a new class of organometallic "piano-stool" Ru(II) and Os(II) arene anticancer complexes of the type [(η(6)-arene)Ru/Os(XY)Cl](+). Here XY is, for example, ethylenediamine (en), and the arene ligand can take many forms, including tetrahydroanthracene, biphenyl, or p-cymene. Arene-nucleobase stacking interactions can have a significant influence on both the kinetics and thermodynamics of DNA binding. In particular, the cytotoxic activity, conformational distortions, recognition by DNA-binding proteins, and repair mechanisms are dependent on the arene. A major difficulty in developing anticancer drugs is cross-resistance, a phenomenon whereby a cell that is resistant to one drug is also resistant to another drug in the same class. These new complexes are non-cross-resistant with cisplatin towards cancer cells: they constitute a new class of anticancer agents, with a mechanism of action that differs from the anticancer drug cisplatin and its analogs. The Ru-arene complexes with dual functions are more potent towards cancer cells than their nonintercalating analogs. In this Account, we focus on recent studies of dual-function organometallic Ru(II)- and Os(II)-arene complexes and the methods used to detect arene-DNA intercalation. We relate these interactions to the mechanism of anticancer activity and to structure-activity relationships. The interactions between these complexes and DNA show close similarities to those of covalent polycyclic aromatic carcinogens, especially to N7-alkylating intercalation compounds. However, Ru-arene complexes exhibit some new features. Classical intercalation and base extrusion next to the metallated base is observed for {(η(6)-biphenyl)Ru(ethylenediamine)}(2+) adducts of a 14-mer duplex, while penetrating arene intercalation occurs for adducts of the nonaromatic bulky intercalator {(η(6)-tetrahydroanthracene)Ru(ethylenediamine)}(2+) with a 6-mer duplex. The introduction of dual-function Ru-arene complexes introduces new mechanisms of antitumor activity, novel mechanisms for attack on DNA, and new concepts for developing structure- activity relationships. We hope this discussion will stimulate thoughtful and focused research on the design of anticancer chemotherapeutic agents using these unique approaches.

Penetrative Dna Intercalation and G-Base Selectivity of an Organometallic Tetrahydroanthracene Ru-Ii Anticancer Complex

Ruthenation of duplex and single-stranded d(CGGCCG) by organometallic anticancer complexes.

Thymines in Single-Stranded Oligonucleotides and G-Quadruplex Dna Are Competitive with Guanines for Binding to an Organoruthenium Anticancer Complex

Binding of Organometallic Ruthenium Anticancer Complexes to DNA: Thermodynamic Base and Sequence Selectivity.

"Head-to-head" double-hamburger-like structure of di-ruthenated d(GpG) adducts of mono-functional Ru-arene anticancer complexes.

Synthesis, Characterization and Biological Evaluation of Labile Intercalative Ruthenium(ii) Complexes for Anticancer Drug Screening.

Metal Complexes As DNA Intercalators.

DNA-Binding Capabilities and Anticancer Activities of Ruthenium(II) Cymene Complexes with (poly)cyclic Aromatic Diamine Ligands.

Binding to Dna Purine Base and Structure-Activity Relationship of A Series of Structurally Related Ru(Ii) Antitumor Complexes: A Theoretical Study

Targeting nucleus DNA with a cyclometalated dipyridophenazineruthenium(II) complex.

Mechanism of interstrand migration of organoruthenium anticancer complexes within a DNA duplex.

Dual-targeting organometallic ruthenium(II) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands

Comparative Studies on DNA-binding and in Vitro Antitumor Activity of Enantiomeric Ruthenium(ii) Complexes.

Enhanced DNA damage and anti-proliferative activity of a novel ruthenium complex with a chlorambucil-decorated ligand

Selective anticancer activities of ruthenium(II)-tetrazole complexes and their mechanistic insights

DNA Targeting Rigid Dinuclear Ruthenium-Arene Complexes

Dna Binding and Photocleavage Properties and Apoptosis-Inducing Activities of A Ruthenium Porphyrin Complex [(Py-3 ')Tpp-Ru(phen)(2)cl]cl and Its Heterometallic Derivatives

Rigid dinuclear ruthenium-arene complexes showing strong DNA interactions.

Tandem Mass Spectrometry Reveals Preferential Ruthenation of Thymines in Human Telomeric G-Quadruplex DNA by an Organometallic Ruthenium Anticancer Complex

DNA Binding, Cytotoxicity, and Apoptotic-Inducing Activity of Ruthenium(ii) Polypyridyl Complex

Polynuclear ruthenium organometallic complexes containing a 1,3,5-triazine ligand: synthesis, DNA interaction, and biological activity